Researchers investigated the potential association between cutaneous lymphoma and anti-TNFα therapy in a recent study.

FDA Alerts

FDA Alerts
Tuesday, August 29, 2017
The FDA has approved adalimumab-adbm (Cyltezo), a biosimilar of Humira (adalimumab), for the treatment of multiple inflammatory diseases.
FDA Alerts
Friday, July 14, 2017
The FDA has approved an injectable treatment for moderate to severe plaque psoriasis in adult patients.
FDA Alerts
Friday, July 7, 2017
The FDA has approved the intravenous (IV) and subcutaneous injection (SC) formulations of abatacept (Orencia; Bristol-Myers Squibb) for the treatment of active psoriatic arthritis (PsA) in adult patients.
FDA Alerts
Wednesday, May 24, 2017
The FDA has accepted the Biologics License Application (BLA) for tildrakizumab (Sun Pharmaceutical Industries Ltd), an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis.

News

News
Friday, December 15, 2017
Health care utilization in the United States often differs by race and ethnicity. However, less data currently exists about whether health care utilization for skin diseases in particular differs by race.
News
Friday, December 8, 2017
Skin conditions such as psoriasis occur more often in individuals who are overweight or obese compared with people who are healthy. In a recent study, researchers aimed to determine whether the severity of psoriasis is affected by body mass index.
News
Thursday, December 7, 2017
Medication nonadherence often disrupts the therapeutic benefit of psoriasis treatment. In a recent study, researchers evaluated potential barriers to treatment adherence in patients with psoriasis.
News
Monday, November 27, 2017
Researchers recently examined the link between bariatric surgery and risk for psoriasis among patients with obesity.

NPF Endorsed Articles

NPF Endorsed Articles
Friday, December 18, 2015
New research finds the incidence of psoriatic arthritis (PsA) among patients with psoriasis is much greater than previously thought.
NPF Endorsed Articles
Friday, December 18, 2015
  This article reviews the current biologic therapies for the treatment of psoriasis and psoriatic arthritis, discusses the importance of patient and clinician education in the decision-making process and highlights drugs in the pipeline.
NPF Endorsed Articles
Wednesday, December 16, 2015
Researchers conducted a retrospective analysis of a group of adolescents (age <17 years) and children with plaque psoriasis treated with cyclosporine at multiple dermatology clinics in Italy. They set out to evaluate the efficacy and safety of the treatment in childhood/adolescent psoriasis in a population of 38 participants. The length of therapy varied from 1 to 36 months, and the median maintenance dosage per day was 3.2 mg/kg. 
NPF Endorsed Articles
Tuesday, November 17, 2015
In this excerpt from the recently published book, Practical Psoriasis Management, the authors discuss the use of  cyclosporine for acute treatment of severe psoriasis and when other systemic medications have failed. 

Research in Review

Research in Review
Friday, September 8, 2017
Starting a support group for patients with psoriasis has many benefits and some challenges, too.
Research in Review
Wednesday, August 9, 2017
Kaiser Permanente researcher and clinician has studied how inflammatory effects of psoriasis can impact the entire body.
Research in Review
Monday, July 3, 2017
In this case, a 37-year-old man presented to the clinic seeking continuing care for a chronic, pruritic, bilateral rash. On physical examination, well-defined erythematous patches and papules with overlying scale were present on the anterior and posterior portion of the lower extremities.
Research in Review
Friday, June 30, 2017
In this case, a 62-year-old female has been on medication for over 1 year for treatment of psoriasis and presents with a tender eruption of 3 days duration on her right arm.